Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways

Comparative effects of incretin-based therapy on doxorubicin-induced nephrotoxicity in rats: the role of SIRT1/Nrf2/NF-κB/TNF-α signaling pathways

Introduction: Nephrotoxicity represents a major complication of using doxorubicin (DOX) in the management of several types of cancers. Increased oxidative stress and the activation of inflammatory mediators play outstanding roles in the development of DOX-induced kidney damage. This study aimed to i...

Full description

Bibliographic Details
Main Authors:	Sandy R. Botros, Asmaa I. Matouk, Amr Amin, Gehan H. Heeba
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Pharmacology
Subjects:	doxorubicin nephrotoxicity incretins glucagon-like peptide-1 dipeptidyl peptidase-4 inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1353029/full

Similar Items

Incretin-based therapy: renal effects
by: Anton Ivanovich Korbut, et al.
Published: (2016-01-01)

Pathogenetic substantiation and effectiveness of vildagliptin use inpatients with diabetes mellitus type 2
Published: (2009-09-01)

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
by: Anand-Krishna Singh, et al.
Published: (2021-06-01)

Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study
by: Arunkumar Krishnan, et al.
Published: (2024-12-01)

Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials
by: Mahmoud Barbarawi, et al.
Published: (2018-11-01)

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review
by: L. M. Pechmann, et al.
Published: (2024-07-01)

Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy
by: Chor Ho Jo, et al.
Published: (2018-06-01)

Lechenie sakharnogo diabeta 2 tipa ingibitorami dipeptidilpeptidazy-4
Published: (2010-09-01)

Updates of incretin‐related drugs for the treatment of type 2 diabetes
by: Hirotaka Araki, et al.
Published: (2023-02-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

The role of incretin-based therapies in the management of type 2 diabetes mellitus: perspectives on the past, present and future
by: Juris J. Meier
Published: (2019-12-01)

Incretins today: multiple effects and therapeutic potential
by: Oksana V. Tsygankova, et al.
Published: (2019-03-01)

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
by: Nasser Mikhail
Published: (2008-12-01)

Can Dexrazoxane and Carvedilol prevent Doxorubicin-induced nephrotoxicity?
by: Szponar Jaroslaw, et al.
Published: (2024-12-01)

<i>Withania somnifera</i> Ameliorates Doxorubicin-Induced Nephrotoxicity and Potentiates Its Therapeutic Efficacy Targeting SIRT1/Nrf2, Oxidative Stress, Inflammation, and Apoptosis
by: Amany Mohammed Mohmmed Hegab, et al.
Published: (2025-02-01)

Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology
by: Bhaskar Pal, et al.
Published: (2024-01-01)

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
by: Giuseppe Lisco, et al.
Published: (2023-10-01)

Gossypetin mitigates doxorubicin-induced nephrotoxicity: A histopathological and biochemical evaluation
by: Muhammad Umar Ijaz, et al.
Published: (2023-10-01)

Incretin Mimetics in the Indian Context: Revisiting Exenatide
by: Shambo S Samajdar, et al.
Published: (2022-08-01)

Cancer Biology and Prevention in Diabetes
by: Swayam Prakash Srivastava, et al.
Published: (2020-06-01)

The protective effect of hydroalcoholic Citrus aurantifolia peel extract against doxorubicin-induced nephrotoxicity
by: Ni Made Dwi Sandhiutami, et al.
Published: (2024-10-01)

Amla (Emblica officinalis) alleviates doxorubicin-induced cardiotoxicity and nephrotoxicity in rats
by: Mandeep Kumar Arora, et al.
Published: (2024-06-01)

Las incretinas: nueva alternativa terapéutica para el control glucometabólico de la diabetes mellitus de tipo 2 Incretins: a new therapeutic alternative for the glycometabolic control of the type 2 diabetes mellitus
by: Yaily Lazo Roblejo, et al.
Published: (2012-03-01)

Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis
by: Akira Mima, et al.
Published: (2023-03-01)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
by: Kushner P
Published: (2010-04-01)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
by: Szymon Jonik, et al.
Published: (2022-02-01)

The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects
by: Akihiro Hamasaki, et al.
Published: (2024-06-01)

Citrus aurantifolia (Chrism.) Swingle peel extract attenuate nephrotoxicity induced by doxorubicin
by: Elijah O. Oyinloye, et al.
Published: (2024-06-01)

Dipeptidyl peptidase IV and its implication in cancer
by: Yarini M Arrebola, et al.

CARDIOPRODUCTIVE EFFECTS OF EXXENATE AMID AND VILDAGLIPTIN INCRETIN MIMETICS IN DOXYRUBRICINE CARDIOMYOPATHY MODELING
by: A. P. TARASOVА, et al.
Published: (2017-09-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01)

Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
by: Shangyu Chai, et al.
Published: (2022-10-01)

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
by: Katherine O. Kopp, et al.
Published: (2024-07-01)

determine the effects of resistance training on serum levels of GLP-1, DPP-4 and insulin resistance in obese men
by: Asieh Abbassi-Daloii, et al.
Published: (2017-05-01)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
by: Ahren B
Published: (2010-03-01)

Tirzepatide – a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023-10-01)

The Regulation of Metabolic Homeostasis by Incretins and the Metabolic Hormones Produced by Pancreatic Islets
by: Reed J, et al.
Published: (2024-06-01)

Anti-Inflammatory, Anti-Apoptotic, and Antioxidant Roles of Honey, Royal Jelly, and Propolis in Suppressing Nephrotoxicity Induced by Doxorubicin in Male Albino Rats
by: Hanaa K. Mohamed, et al.
Published: (2022-05-01)

Variation in responses to incretin therapy: Modifiable and non-modifiable factors
by: Gregory O. Austin, et al.
Published: (2023-04-01)

Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01)